Survodutide for Fat Loss
Investigational GLP-1 / glucagon dual agonist from Boehringer Ingelheim and Zealand Pharma.
Why Survodutide for fat loss?
Survodutide (BI 456906) is a weekly GLP-1R / glucagon-receptor co-agonist co-developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 in obesity reported up to 19% weight loss at 46 weeks, and a 2024 MASH trial demonstrated significant fibrosis improvement. Phase 3 SYNCHRONIZE program is ongoing.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Survodutide fits this goal because its category (Metabolic) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Strong weight loss (~19% Phase 2)
- MASH liver-fat reduction
Reference dosing by bodyweight
Anchored to the most-cited research dose (600 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 374–506 mcg |
| 60–75 kg / 132–165 lb | 459–621 mcg |
| 75–90 kg / 165–198 lb | 561–759 mcg |
| 90–105 kg / 198–231 lb | 663–897 mcg |
| >105 kg / >231 lb | 765–1035 mcg |
Side effects to weigh against fat loss benefit
- GI side effects (dose-limiting)
- Increased heart rate
- Injection-site reactions
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.